Lokivetmab

• Description:

  Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD) . Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs[1].

• Product Name Alternative:

  Anti-Canine IL31 Recombinant Antibody; CAN34D3-65; PF-06443537

• UNSPSC:

  12352203

• Target:

  Interleukin Related

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/lokivetmab.html

• Purity:

  99.0

• Solubility:

  H2O

• Smiles:

  [Lokivetmab]

• Molecular Weight:

  (147.51 kDa)

• References & Citations:

  [1]Gober M, et al. Long term use of lokivetmab (Cytopoint®) in atopic dogs. BMC Vet Res. 2025 Mar 26;21 (1) :203.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported

• CAS Number:

  [1533403-95-0]